Benjamin G Neel

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer M, et al. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discov. 2018;8:1237-1249 pubmed publisher
    ..i>Cancer Discov; 8(10); 1237-49. ©2018 AACR. See related commentary by Torres-Ayuso and Brognard, p. 1210 This article is highlighted in the In This Issue feature, p. 1195. ..
  2. Xu Y, Taylor P, Andrade J, Ueberheide B, Shuch B, Glazer P, et al. Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Res. 2018;78:6539-6548 pubmed publisher
    ..SIGNIFICANCE: This work identifies a novel mechanism of activation of the oncogenic kinase ABL1 via ROS-induced, oxidation-mediated inactivation of cognate protein tyrosine phosphatases. ..
  3. Ran H, Tsutsumi R, Araki T, Neel B. Sticking It to Cancer with Molecular Glue for SHP2. Cancer Cell. 2016;30:194-196 pubmed publisher
    ..A recent report, describing a highly specific, orally bioavailable inhibitor of the PTP oncoprotein SHP2 with in vivo activity, suggests that allostery might provide a way forward for PTP inhibitor development. ..
  4. Cybulska P, Stewart J, Sayad A, Virtanen C, Shaw P, Clarke B, et al. A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. Am J Pathol. 2018;188:1120-1131 pubmed publisher
    ..Credentialing of PDX models of HGSC should aid progress in HGSC research by providing improved preclinical models of HGSC that can be used to test novel targets and more accurately evaluate their likelihood of success. ..
  5. Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin G, Wang J, et al. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell. 2017;170:1079-1095.e20 pubmed publisher
    ..paperclip. ..
  6. Wang L, Iorio C, Yan K, Yang H, Takeshita S, Kang S, et al. A ERK/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K/AKT activation in macrophages. FASEB J. 2017;: pubmed publisher
    ..Wang, L., Iorio, C., Yan, K., Yang, H., Takeshita, S., Kang, S., Neel, B.G., Yang, W. An ERK/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K/AKT activation in macrophages...
  7. Marcotte R, Sayad A, Brown K, Sanchez Garcia F, Reimand J, Haider M, et al. Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell. 2016;164:293-309 pubmed publisher
    ..Finally, we demonstrate the utility of this large dataset by identifying BRD4 as a potential target in luminal breast cancer and PIK3CA mutations as a resistance determinant for BET-inhibitors. ..
  8. Zhang X, Dong Z, Zhang C, Ung C, He S, Tao T, et al. Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. Cell Rep. 2017;18:2932-2942 pubmed publisher
    ..Our findings further suggest that combined inhibition of MYCN and the SHP2-RAS-ERK pathway could provide effective targeted therapy for high-risk neuroblastoma patients with MYCN amplification and aberrant SHP2 activation. ..